NewswireToday - /newswire/ -
Palo Alto, CA, United States, 2006/02/22 - New analysis from Frost & Sullivan (pharma.frost.com), Strategic Analysis of U.S. Hepatitis B and C Markets, reveals that hepatitis markets earned revenue of $ 2,180.0 million in 2005 and estimates to reach $4,778.1 million in 2012..
There is a huge unmet need in hepatitis B and C treatments, which has seen problems with the emergence of viral resistance and side effects. The huge potential offered by the market has encouraged companies to build a strong pipeline of therapies.
New analysis from Frost & Sullivan (pharma.frost.com), Strategic Analysis of U.S. Hepatitis B and C Markets, reveals that hepatitis markets earned revenue of $ 2,180.0 million in 2005 and estimates to reach $4,778.1 million in 2012.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the Strategic Analysis of U.S. Hepatitis B and C Markets then send an e-mail to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.
"Hepatitis B and C markets suffer from the lack of effective treatment options resulting in low treatment rates," notes Frost & Sullivan Research Analyst Barath Shankar.
The existing therapies have side-effects that restraints usage and poses and additional challenge of side-effects and co-infection management.
Large undiagnosed population of hepatitis B and C carriers is growing and the absence of effective treatment options has resulted in low treatment rates. However, newer and effective treatments are likely to be launched, which are expected to aid in an increase in diagnosis and treatment rates.
"The existing therapeutic options are likely to loose their market shares to newer therapies that are expected to be launched," explains Barath Shankar. "The market is likely to grow to be more competitive with more companies expected to enter market."
Pharmaceutical companies need to focus on improving efficacy, manage side-effects and overcome viral resistance that has arisen from older therapeutic options.
Strategic Analysis of U.S. Hepatitis B and C Markets, a part of the pharmaceuticals and biotechnology subscription service, provides an overview and outlook for the market. This study has been segmented as hepatitis B and C markets. This research includes detailed patient, pricing and revenue forecasts, industry trends and market share analysis that have been evaluated following extensive interviews with market participants. Interviews are available to the press.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.
Strategic Analysis of U.S. Hepatitis B and C Markets